EXAI
Exscientia Ltd - ADR

682
Loading...
Loading...
News
all
press releases
Exscientia Achieves Milestones for Two Programmes in Sanofi Collaboration
Exscientia plc (Nasdaq: EXAI) today announced the advancement of two additional discovery programmes within its collaboration with Sanofi, with Exscientia receiving an aggregate of $15 million in...
Business Wire·11mo ago
News Placeholder
More News
News Placeholder
Exscientia to Present New Preclinical Data for AI-designed LSD1 and MALT1 Inhibitors at ENA 2024
Exscientia plc (Nasdaq: EXAI) today announced three abstracts to be presented at the 36th EORTC-NCI-AACR (ENA) Symposium 2024 from October 23-25, in Barcelona, Spain. As our precision-designed LSD1...
Business Wire·11mo ago
News Placeholder
AI Revolution in Healthcare Gains Momentum as FDA Prepares for Tech Boom
AI Revolution in Healthcare Gains Momentum as FDA Prepares for Tech Boom AI Revolution in Healthcare Gains Momentum as FDA Prepares for Tech Boom PR Newswire VANCOUVER, BC, Sept. 24, 2024 USA News...
PR Newswire·1y ago
News Placeholder
Exscientia Plc Backs Acquisition by Recursion Pharmaceuticals
Exscientia Plc (EXAI) has released an update. Exscientia Plc has committed to an irrevocable undertaking favoring the acquisition of its issued and...
TipRanks Financial Blog·1y ago
News Placeholder
Exscientia to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
Exscientia plc (Nasdaq: EXAI) today announced that David Hallett, interim Chief Executive Officer and Chief Scientific Officer, will participate in a fireside chat at the Morgan Stanley 22nd Annual...
Business Wire·1y ago
News Placeholder
Morgan Stanley Sticks to Their Hold Rating for Exscientia Plc (EXAI)
In a report released today, Vikram Purohit from Morgan Stanley maintained a Hold rating on Exscientia Plc (EXAI Research Report), with a price ta...
TipRanks Financial Blog·1y ago
News Placeholder
Exscientia Business Update for Second Quarter and First Half 2024
Exscientia plc (Nasdaq: EXAI): Recent advancements in the Companys pipeline, collaborations and operations, as well as financial results for the second quarter and first half 2024, are summarised...
Business Wire·1y ago
News Placeholder
Recursion CEO on $688M Exscientia acquisition: Hope to bring better medicines to patients sooner
Recursion CEO on $688M Exscientia acquisition: Hope to bring better medicines to patients sooner...
CNBC Television-YouTube·1y ago
News Placeholder
AI-Powered Drug Discovery Firm Exscientia To Merge With Nvidia-Partner Recursion Pharmaceuticals
AI-Powered Drug Discovery Firm Exscientia To Merge With Nvidia-Partner Recursion Pharmaceuticals...
Yahoo! Finance: News·1y ago
News Placeholder
AI-Powered Drug Discovery Firm Exscientia To Merge With Nvidia-Partner Recursion Pharmaceuticals
Exscientia merges with Recursion Pharmaceuticals in an all-stock deal. The new entity, named Recursion, will focus on industrializing drug discovery with advanced AI technologies, boasting $850...
Benzinga·1y ago

Latest EXAI News

View

Advertisement. Remove ads.

Advertisement. Remove ads.